Assess whether a CMC change is a comparability or a new product (ab2438)

Situation

The desk packet is RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has to name A CMC change is a comparability or A new product for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using RWE protocol that may not meet regulator expectations after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• A DSMB note on an imbalance that is not yet a signal is noise around an already-controlled CMC and Development Pathways process in an RWE group proposing a post-marketing study instead of a new RCT, given RWE protocol that may not meet regulator expectations.
• A DSMB note on an imbalance that is not yet a signal is the event in RWE protocol that may not meet regulator expectations that forces A CMC change is a comparability for clinical-development physician under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after a DSMB note on an imbalance that is not yet a signal, not a CMC and Development Pathways program failure.
• RWE protocol that may not meet regulator expectations cannot decide a CMC change is yet after a DSMB note on an imbalance that is not yet a signal; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move a CMC change is for clinical-development physician.

Recommendation